New hope for advanced lung cancer: drug plus Low-Dose radiation trial opens
NCT ID NCT04170946
First seen Mar 13, 2026 · Last updated May 11, 2026 · Updated 10 times
Summary
This early-stage study is testing the safety of combining the drug talazoparib with low-dose chest radiation in people with extensive-stage small cell lung cancer. Up to 24 participants who have finished initial chemotherapy without their cancer getting worse will take talazoparib pills daily during radiation. The goal is to find the highest safe dose and see if this combination helps control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Princess Margaret Cancer Center, University Health Network
RECRUITINGToronto, Ontario, M5G 2M9, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.